DK3178944T3 - Fremgangsmåde til anvendelse af genekspression til bestemmelse af sandsynligheden for et klinisk resultat for nyrecancer - Google Patents

Fremgangsmåde til anvendelse af genekspression til bestemmelse af sandsynligheden for et klinisk resultat for nyrecancer Download PDF

Info

Publication number
DK3178944T3
DK3178944T3 DK17153152.8T DK17153152T DK3178944T3 DK 3178944 T3 DK3178944 T3 DK 3178944T3 DK 17153152 T DK17153152 T DK 17153152T DK 3178944 T3 DK3178944 T3 DK 3178944T3
Authority
DK
Denmark
Prior art keywords
likelihood
risk
gene expression
clinical result
applying gene
Prior art date
Application number
DK17153152.8T
Other languages
Danish (da)
English (en)
Inventor
Steven Shak
Audrey Goddard
Dejan Knezevic
Tara Maddala
Frederick L Baehner
Wayne Cowens
Joffre B Baker
Michael C Kiefer
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Application granted granted Critical
Publication of DK3178944T3 publication Critical patent/DK3178944T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N7/00—Computing arrangements based on specific mathematical models
    • G06N7/01—Probabilistic graphical models, e.g. probabilistic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B99/00—Subject matter not provided for in other groups of this subclass
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Data Mining & Analysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Mathematical Optimization (AREA)
  • Pure & Applied Mathematics (AREA)
  • Artificial Intelligence (AREA)
  • Algebra (AREA)
  • Probability & Statistics with Applications (AREA)
DK17153152.8T 2010-01-11 2011-01-07 Fremgangsmåde til anvendelse af genekspression til bestemmelse af sandsynligheden for et klinisk resultat for nyrecancer DK3178944T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29403810P 2010-01-11 2010-01-11
US34623010P 2010-05-19 2010-05-19
EP15203193.6A EP3029155A3 (en) 2010-01-11 2011-01-07 Method to use gene expression to determine likelihood of clinical outcome of renal cancer

Publications (1)

Publication Number Publication Date
DK3178944T3 true DK3178944T3 (da) 2019-08-12

Family

ID=44258831

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17153152.8T DK3178944T3 (da) 2010-01-11 2011-01-07 Fremgangsmåde til anvendelse af genekspression til bestemmelse af sandsynligheden for et klinisk resultat for nyrecancer

Country Status (12)

Country Link
US (4) US9551034B2 (https=)
EP (5) EP3178944B1 (https=)
JP (5) JP6286124B2 (https=)
AU (1) AU2011203977B2 (https=)
CA (3) CA3128103C (https=)
DK (1) DK3178944T3 (https=)
ES (2) ES2741379T3 (https=)
IL (6) IL219978A (https=)
MX (3) MX341866B (https=)
NZ (4) NZ617003A (https=)
SG (1) SG181806A1 (https=)
WO (1) WO2011085263A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3178944B1 (en) 2010-01-11 2019-05-15 Genomic Health, Inc. Method to use gene expression to determine likelihood of clinical outcome of renal cancer
MX338883B (es) 2010-07-27 2016-05-04 Genomic Health Inc Metodo para usar expresion de gen para determinar el pronostico de cancer de prostata.
SG187045A1 (en) 2010-08-13 2013-02-28 Somalogic Inc Pancreatic cancer biomarkers and uses thereof
WO2013016673A2 (en) * 2011-07-27 2013-01-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of dpep1 and tpx2 expression for evaluating treatment or survival time of patients with pancreatic ductal adenocarcinoma
EP2748356A2 (en) * 2011-08-22 2014-07-02 Somalogic, Inc. Renal cell carcinoma biomarkers and uses thereof
HK1212389A1 (en) 2011-10-24 2016-06-10 Signalchem Lifesciences Corporation Carbonic anhydrase ix-related markers and use thereof
US8725426B2 (en) 2012-01-31 2014-05-13 Genomic Health, Inc. Gene expression profile algorithm and test for determining prognosis of prostate cancer
JP2016521979A (ja) * 2013-05-30 2016-07-28 ジェノミック ヘルス， インコーポレイテッド 腎臓がんを有する患者に対する再発スコアを計算するための遺伝子発現プロファイルアルゴリズム
SG11201602019XA (en) * 2013-09-17 2016-04-28 Agency Science Tech & Res Multigene assay for prognosis of renal cancer
WO2016034611A1 (en) * 2014-09-02 2016-03-10 Max-Delbrück-Centrum für Molekulare Medizin Antisense oligonucleotides targeting 3'utr region of a20
JP6638128B2 (ja) * 2014-10-30 2020-01-29 公立大学法人福島県立医科大学 腎がんの悪性度の検査マーカー及び検査方法
WO2016126883A1 (en) * 2015-02-03 2016-08-11 Cedars-Sinai Medical Center Biomarker based prognostic model for predicting overall survival in patients with metastatic clear cell kidney cancer
GB201616912D0 (en) 2016-10-05 2016-11-16 University Of East Anglia Classification of cancer
CN110546277B (zh) 2017-03-01 2024-06-11 豪夫迈·罗氏有限公司 用于癌症的诊断和治疗方法
WO2018161027A1 (en) * 2017-03-03 2018-09-07 Oregon State University Antisense antibacterial compounds and methods
US10636512B2 (en) 2017-07-14 2020-04-28 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
US11335464B2 (en) * 2018-01-12 2022-05-17 Siemens Medical Solutions Usa, Inc. Integrated precision medicine by combining quantitative imaging techniques with quantitative genomics for improved decision making
CA3105292A1 (en) * 2018-08-10 2020-02-13 Omniseq, Inc. Methods and systems for assessing proliferative potential and resistance to immune checkpoint blockade
WO2020085936A1 (ru) * 2018-10-24 2020-04-30 Общество С Ограниченной Ответственностью "Онкобокс" Тест-классификатор клинического ответа на лечение сорафенибом индивидуальных пациентов с раком почки
US11845989B2 (en) 2019-01-23 2023-12-19 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
JP2022523301A (ja) 2019-01-23 2022-04-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アンジオポエチン様７（ａｎｇｐｔｌ７）阻害剤による眼疾患の治療
WO2021030604A1 (en) * 2019-08-14 2021-02-18 University Of Massachusetts Urinary rna signatures in renal cell carcinoma (rcc)
WO2022182768A1 (en) 2021-02-26 2022-09-01 Regeneron Pharmaceuticals, Inc. Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (angptl7) inhibitors
CN113025716A (zh) * 2021-03-02 2021-06-25 北京大学第一医院 一种用于人肿瘤分级的基因组合及其用途
CN113817816A (zh) * 2021-10-08 2021-12-21 济南艾迪康医学检验中心有限公司 检测epas1基因突变的引物、试剂盒和方法
WO2023080900A1 (en) * 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
CN118711678B (zh) * 2024-08-22 2025-12-12 暨南大学附属第一医院（广州华侨医院） 一种肾透明细胞肿瘤预测方法、装置、设备及存储介质

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US7135314B1 (en) * 1997-04-17 2006-11-14 Cell Therapeutics, Inc. Human phosphatidic acid phosphatase
CA2397207C (en) * 2000-01-13 2013-12-03 Genentech, Inc. Novel stra6 polypeptides
DE10126344A1 (de) * 2000-07-14 2002-01-24 Max Planck Gesellschaft Apoptose-induzierende DNA-Sequenzen
WO2002027028A1 (en) * 2000-09-28 2002-04-04 Atairgin Technologies, Inc. A method of determining tumor characteristics by determining abnormal copy number or expression level of lipid-associated genes
US20030109434A1 (en) * 2001-03-19 2003-06-12 Corixa Corporation Compositions and methods for the therapy and diagnosis of kidney cancer
CA2442820A1 (en) * 2001-03-29 2002-10-10 Van Andel Institute Microarray gene expression profiling in clear cell renal cell carcinoma: prognosis and drug target identification
JP2005500832A (ja) * 2001-06-18 2005-01-13 ロゼッタ・インファーマティクス・インコーポレーテッド 乳癌患者の診断および予後
US7470509B2 (en) 2002-02-08 2008-12-30 Millennium Pharmaceuticals, Inc. Compositions and methods for the identification, assessment, prevention and therapy of ovarian cancer
CA2992643C (en) 2002-03-13 2019-06-18 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
AU2003288918A1 (en) * 2002-10-04 2004-05-04 Van Andel Research Institute Molecular sub-classification of kidney tumors and the discovery of new diagnostic markers
AU2003298689A1 (en) 2002-11-21 2004-06-18 Wyeth Methods for diagnosing rcc and other solid tumors
WO2004097052A2 (en) 2003-04-29 2004-11-11 Wyeth Methods for prognosis and treatment of solid tumors
ES2609234T3 (es) 2003-06-24 2017-04-19 Genomic Health, Inc. Predicción de la probabilidad de recidiva de cáncer
EP1644522A2 (en) 2003-07-02 2006-04-12 Novartis AG Genes regulated in ovarian cancer as prognostic and therapeutic targets
US20050002904A1 (en) * 2003-07-03 2005-01-06 Wary Kishore K. Uses of vascular endothelial growth factor and type I collagen inducible protein (VCIP)
US7526387B2 (en) 2003-07-10 2009-04-28 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
WO2005024603A2 (en) 2003-09-10 2005-03-17 The Board Of Regents Of The University Of Texas System Methods for detecting, diagnosing and treating human renal cell carcinoma
JP2005211023A (ja) * 2004-01-30 2005-08-11 Hayashibara Biochem Lab Inc 腎細胞癌の転移若しくは再発の可能性を予測する方法
US20070224596A1 (en) * 2004-04-09 2007-09-27 Mariana Nacht Compositions and methods for the modifying hypoxia induced gene regulation
CA2563074C (en) 2004-04-09 2014-05-20 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
WO2005117943A2 (en) * 2004-05-27 2005-12-15 Vertex Pharmaceuticals Incorporated Biomarkers for monitoring inhibition of impdh pathway
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
US20080119367A1 (en) * 2004-12-17 2008-05-22 Mayo Foundation For Medical Education And Research Prognosis of Renal Cell Carcinoma
US20090258002A1 (en) 2005-02-01 2009-10-15 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Biomarkers for Tissue Status
CN101120255A (zh) 2005-02-18 2008-02-06 惠氏公司 用于实体肿瘤预后的药物基因组学标志
WO2006124022A1 (en) * 2005-05-13 2006-11-23 Vanandel Research Institute Microarray gene expression profiling in subtypes of clear cell renal cell carcinoma
US20090186024A1 (en) 2005-05-13 2009-07-23 Nevins Joseph R Gene Expression Signatures for Oncogenic Pathway Deregulation
US20070037186A1 (en) * 2005-05-20 2007-02-15 Yuqiu Jiang Thyroid fine needle aspiration molecular assay
CA2611728A1 (en) * 2005-06-08 2006-12-14 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with cancer therapy
WO2006135886A2 (en) * 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1907858A4 (en) * 2005-06-13 2009-04-08 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
DE602006012042D1 (de) * 2005-06-15 2010-03-18 Pfizer Ltd Substituierte arylpyrazole zur verwendung gegen parasiten
KR101446626B1 (ko) * 2005-09-02 2014-10-06 도레이 카부시키가이샤 신장암 진단, 신장암 환자 예후 예측을 위한 조성물 및 방법
CN101292046B (zh) 2005-09-14 2013-03-13 人类遗传标记控股有限公司 健康状态的测定法
EP2332984A3 (en) * 2005-09-30 2011-10-12 Universiteit Maastricht Tumor angiogenesis associated genes and a method for their identification
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
US8445198B2 (en) * 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
CN101365806B (zh) 2005-12-01 2016-11-16 医学预后研究所 用于鉴定治疗反应的生物标记的方法和装置及其预测疗效的用途
US20070141066A1 (en) 2005-12-16 2007-06-21 Genentech, Inc. Method for Diagnosing, Prognosing and Treating Glioma
WO2007146668A2 (en) * 2006-06-06 2007-12-21 University Of Massachusetts Use of imp3 as a prognostic marker for cancer
EP2046973A4 (en) * 2006-08-10 2010-04-07 Millennium Pharm Inc IDENTIFICATION, ASSESSMENT AND TREATMENT OF CANCER THERAPY PATIENTS
WO2008021115A2 (en) 2006-08-14 2008-02-21 The Brigham And Women's Hospital, Inc. Diagnostic tests using gene expression ratios
WO2008083098A1 (en) 2006-12-27 2008-07-10 The Johns Hopkins University Agents for reversing epigenetic silencing of genes
US20080286273A1 (en) 2007-05-02 2008-11-20 Siemens Medical Solutions Usa, Inc. Knowledge-Based Proliferation Signatures and Methods of Use
EP1990417A1 (en) 2007-05-11 2008-11-12 Universität Bayreuth Archaeal plasmid vector system
WO2009105640A1 (en) 2008-02-22 2009-08-27 Virginia Commonwealth University Signatures associated with rejection or recurrence of cancer
WO2010056374A2 (en) 2008-11-17 2010-05-20 Veracyte, Inc. Methods and compositions of molecular profiling for disease diagnostics
US20120142553A1 (en) * 2009-06-26 2012-06-07 Franciscus Petrus Smit Molecular Markers in Kidney Cancer
CA3043089A1 (en) 2009-11-23 2011-05-26 Genomic Health, Inc. Methods to predict clinical outcome of cancer
EP3178944B1 (en) 2010-01-11 2019-05-15 Genomic Health, Inc. Method to use gene expression to determine likelihood of clinical outcome of renal cancer
EP2721179A4 (en) 2011-06-16 2014-10-01 Caris Life Sciences Luxembourg Holdings S A R L BIOMARKER COMPOSITIONS AND METHOD THEREFOR
EP2748356A2 (en) 2011-08-22 2014-07-02 Somalogic, Inc. Renal cell carcinoma biomarkers and uses thereof

Also Published As

Publication number Publication date
IL270151B (en) 2021-03-25
JP2017148059A (ja) 2017-08-31
MX2012007882A (es) 2012-08-03
IL256335B (en) 2018-12-31
WO2011085263A2 (en) 2011-07-14
JP2013516195A (ja) 2013-05-13
SG181806A1 (en) 2012-07-30
IL262100A (en) 2018-11-29
AU2011203977A1 (en) 2012-06-21
EP2524055A2 (en) 2012-11-21
EP3178944A2 (en) 2017-06-14
EP3178944B1 (en) 2019-05-15
US20220051755A9 (en) 2022-02-17
EP2524055A4 (en) 2013-06-05
NZ719474A (en) 2018-07-27
JP6286124B2 (ja) 2018-02-28
JP2019162150A (ja) 2019-09-26
NZ600268A (en) 2014-08-29
EP3029155A2 (en) 2016-06-08
IL219978A0 (en) 2012-07-31
IL280689B (en) 2022-01-01
ES2741379T3 (es) 2020-02-10
CA2783858A1 (en) 2011-07-14
NZ705645A (en) 2016-05-27
EP3561078A1 (en) 2019-10-30
US20170121780A1 (en) 2017-05-04
ES3027507T3 (en) 2025-06-16
JP7307602B2 (ja) 2023-07-12
JP7385630B2 (ja) 2023-11-22
IL251635B (en) 2018-04-30
IL251635A0 (en) 2017-06-29
US11776664B2 (en) 2023-10-03
US12412642B2 (en) 2025-09-09
AU2011203977B2 (en) 2015-02-05
IL219978A (en) 2017-04-30
MX2020009704A (es) 2020-10-07
JP2016174600A (ja) 2016-10-06
US20240096451A1 (en) 2024-03-21
CA3128103C (en) 2025-11-18
EP3831964B1 (en) 2025-04-16
JP2021177761A (ja) 2021-11-18
CA2783858C (en) 2021-09-14
NZ617003A (en) 2015-04-24
EP3029155A3 (en) 2016-08-31
MX341866B (es) 2016-09-06
EP3178944A3 (en) 2017-09-13
WO2011085263A3 (en) 2012-01-12
MX375138B (es) 2025-03-06
US20210166790A1 (en) 2021-06-03
JP6546214B2 (ja) 2019-07-17
CA3256492A1 (en) 2025-11-29
CA3128103A1 (en) 2011-07-14
US9551034B2 (en) 2017-01-24
IL262100B (en) 2019-11-28
US10892038B2 (en) 2021-01-12
EP3831964A3 (en) 2021-10-20
US20110171633A1 (en) 2011-07-14
EP3831964A2 (en) 2021-06-09
IL280689A (en) 2021-03-25

Similar Documents

Publication Publication Date Title
DK3178944T3 (da) Fremgangsmåde til anvendelse af genekspression til bestemmelse af sandsynligheden for et klinisk resultat for nyrecancer
DK2772549T3 (da) Fremgangsmåde til detektering af genetisk variation
IL237582A0 (en) Cdk inhibitors
IL227764A0 (en) Pyrrolotriazinone derivatives as pi3k inhibitors
EP2734529A4 (en) BTK INHIBITORS
BR112013020896A2 (pt) adesivos estruturais aperfeiçoados
HUE041411T2 (hu) Genomfrakciók feloldása polimorfizmus-szám alkalmazásával
PL3754990T3 (pl) Sposób wywoływania bloku kandydata łączenia
IL224375B (en) Method for measuring heart rate variability
DK2622532T3 (da) Fremgangsmåde til kollaborativ beregning
BR112014001765A2 (pt) método
BR112014001237A2 (pt) método
EP2773327A4 (en) REPROGRAMMING CELL ADHESION
IL247643A0 (en) Piperidine derivatives
DK2569438T3 (da) Fremgangsmåde til fremstilling af biogas
PT2641833T (pt) Um método de ocultação solar
DK2556168T3 (da) Fremgangsmåde til detektering af specifikke nukleinsyresekvenser
PL393102A1 (pl) Sposób wykonywania destylacji symulowanej
UA21832S (uk) Комплект етикеток
UA21935S (uk) Комплект етикеток
UA23160S (uk) Комплект етикеток
UA21933S (uk) Комплект етикеток
UA22757S (uk) Комплект етикеток
UA23337S (uk) Комплект етикеток
UA23972S (uk) Комплект етикеток